Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells

Journal of Clinical Investigation

Volumn 128, Issue 11, 2018, Pages 4912-4923

  Stanczak, Michal A ^a   Siddiqui, Shoib S ^b   Trefny, Marcel P ^a   Thommen, Daniela S ^a   Boligan, Kayluz Frias ^c   Von Gunten, Stephan ^c   Tzankov, Alexandar ^d   Tietze, Lothar ^e   Lardinois, Didier ^a   Heinzelmann Schwarz, Viola ^a   Von Bergwelt Baildon, Michael ^f   Zhang, Wu ^g   Lenz, Heinz Josef ^g   Han, Younghun ^h   Amos, Christopher I ^h   Syedbasha, Mohammedyaseen ^a   Egli, Adrian ^a   Stenner, Frank ^a   Speiser, Daniel E ⁱ   Varki, Ajit ^b   Zippelius, Alfred ^a   Läubli, Heinz ^a   more..

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e Ortenau Clinics   (Germany)

^f UNIVERSITY OF COLOGNE   (Germany)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h DARTMOUTH COLLEGE   (United States)

ⁱ UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 RECEPTOR; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; SIALOGLYCOPROTEIN; SIGLEC 9; UNCLASSIFIED DRUG; LEUKOCYTE ANTIGEN; SIGLEC9 PROTEIN, HUMAN; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE EVASION; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UPREGULATION; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; MALE; MORTALITY; NEOPLASM; PATHOLOGY; T LYMPHOCYTE; TUMOR CELL LINE;

ANTIGENS, CD; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM PROTEINS; NEOPLASMS; POLYMORPHISM, GENETIC; SIALIC ACID BINDING IMMUNOGLOBULIN-LIKE LECTINS; T-LYMPHOCYTES;

EID: 85054764324     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI120612     Document Type: Article

References (49)

1. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450-461.
2. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321-330.
3. Cao X. Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease. Nat Rev Immunol. 2016;16(1):35-50.
4. Schaefer L. Complexity of danger: the diverse nature of damage-associated molecular patterns. J Biol Chem. 2014;289(51):35237-35245.
5. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev. 2009;22(2):240-273.
6. Chen GY, Nuñez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010;10(12):826-837.
7. Wang RF, Miyahara Y, Wang HY. Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene. 2008;27(2):181-189.
8. Varki A. Since there are PAMPs and DAMPs, there must be SAMPs? Glycan "self-associated molecular patterns" dampen innate immunity, but pathogens can mimic them. Glycobiology. 2011;21(9):1121-1124.
9. Padler-Karavani V, et al. Rapid evolution of binding specificities and expression patterns of inhibitory CD33-related Siglecs in primates. FASEB J. 2014;28(3):1280-1293.
10. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol. 2007;7(4):255-266.
11. Macauley MS, Crocker PR, Paulson JC. Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol. 2014;14(10):653-666.
12. Pearce OM, Läubli H. Sialic acids in cancer biology and immunity. Glycobiology. 2016;26(2):111-128.
13. Nitschke L. CD22 and Siglec-G regulate inhibition of B-cell signaling by sialic acid ligand binding and control B-cell tolerance. Glycobiology. 2014;24(9):807-817.
14. Chang YC, Nizet V. The interplay between Siglecs and sialylated pathogens. Glycobiology. 2014;24(9):818-825.
15. Chang YC, et al. Group B Streptococcus engages an inhibitory Siglec through sialic acid mimicry to blunt innate immune and inflammatory responses in vivo. PLoS Pathog. 2014;10(1):e1003846.
16. Carlin AF, et al. Group B Streptococcus suppression of phagocyte functions by protein-mediated engagement of human Siglec-5. J Exp Med. 2009;206(8):1691-1699.
17. Carlin AF, Uchiyama S, Chang YC, Lewis AL, Nizet V, Varki A. Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response. Blood. 2009;113(14):3333-3336.
18. Schwarz F, et al. Paired Siglec receptors generate opposite inflammatory responses to a human-specific pathogen. EMBO J. 2017;36(6):751-760.
19. Pröpster JM, Yang F, Rabbani S, Ernst B, Allain FH, Schubert M. Structural basis for sulfationdependent self-glycan recognition by the human immune-inhibitory receptor Siglec-8. Proc Natl Acad Sci U S A. 2016;113(29):E4170-E4179.
20. Yu H, et al. Siglec-8 and Siglec-9 binding specificities and endogenous airway ligand distributions and properties. Glycobiology. 2017;27(7):657-668.
21. Läubli H, et al. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proc Natl Acad Sci U S A. 2014;111(39):14211-14216.
22. Jandus C, et al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest. 2014;124(4):1810-1820.
23. Hudak JE, Canham SM, Bertozzi CR. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion. Nat Chem Biol. 2014;10(1):69-75.
24. Läubli H, et al. Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs. J Biol Chem. 2014;289(48):33481-33491.
25. Beatson R, et al. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat Immunol. 2016;17(11):1273-1281.
26. RodrÍguez E, Schetters STT, van Kooyk Y. The tumour glyco-code as a novel immune checkpoint for immunotherapy. Nat Rev Immunol. 2018;18(3):204-211.
27. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486-499.
28. Soto PC, Karris MY, Spina CA, Richman DD, Varki A. Cell-intrinsic mechanism involving Siglec-5 associated with divergent outcomes of HIV-1 infection in human and chimpanzee CD4 T cells. J Mol Med. 2013;91(2):261-270.
29. Nguyen DH, Hurtado-Ziola N, Gagneux P, Varki A. Loss of Siglec expression on T lymphocytes during human evolution. Proc Natl Acad Sci U S A. 2006;103(20):7765-7770.
30. Crocker PR, McMillan SJ, Richards HE. CD33-related siglecs as potential modulators of inflammatory responses. Ann N Y Acad Sci. 2012;1253:102-111.
31. Philip M, et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature. 2017;545(7655):452-456.
32. Wang C, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2(9):846-856.
33. Ishii T, et al. Influence of SIGLEC9 polymorphisms on COPD phenotypes including exacerbation frequency. Respirology. 2017;22(4):684-690.
34. Wang Y, et al. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat Genet. 2014;46(7):736-741.
35. Ikehara Y, Ikehara SK, Paulson JC. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9. J Biol Chem. 2004;279(41):43117-43125.
36. Bandala-Sanchez E, et al. T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10. Nat Immunol. 2013;14(7):741-748.
37. Toubai T, et al. Siglec-G represses DAMP-mediated effects on T cells. JCI Insight. 2017;2(14):e92293.
38. Gordon SR, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545(7655):495-499.
39. Liu Y, et al. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Oncogene. 2017;36(44):6143-6153.
40. Gros A, et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124(5):2246-2259.
41. Thommen DS, et al. Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors. Cancer Immunol Res. 2015;3(12):1344-1355.
42. Legat A, Speiser DE, Pircher H, Zehn D, Fuertes Marraco SA. Inhibitory receptor expression depends more dominantly on differentiation and activation than "exhaustion" of human CD8 T cells. Front Immunol. 2013;4:455.
43. Speiser DE, Ho PC, Verdeil G. Regulatory circuits of T cell function in cancer. Nat Rev Immunol. 2016;16(10):599-611.
44. Rabinovich GA, Croci DO. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity. 2012;36(3):322-335.
45. Perdicchio M, et al. Tumor sialylation impedes T cell mediated anti-tumor responses while promoting tumor associated-regulatory T cells. Oncotarget. 2016;7(8):8771-8782.
46. Cohen M, et al. Sialylation of 3-methylcholanthrene-induced fibrosarcoma determines antitumor immune responses during immunoediting. J Immunol. 2010;185(10):5869-5878.
47. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56-61.
48. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205-214.
49. Melero I, Berman DM, Aznar MA, Korman AJ, Pérez Gracia JL, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015;15(8):457-472.